Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424644 · ClinicalTrials.gov registry record · Phase 4
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
A Phase 4 study of Meningococcal Meningitis, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 801
- Enrollment target
- 20
- Study locations
NCT01424644 is a Phase 4 study of Meningococcal Meningitis that has completed, run by Novartis. The registered enrollment target is 801 participants, above the 541-participant average among 4 other Meningococcal Meningitis trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT01424644, a Phase 4 study of Meningococcal Meningitis, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 801 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by these vaccines when given alone.
Conditions Studied
Interventions
- BIOLOGICAL Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
- BIOLOGICAL MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Study Locations (20)
Nebraska
- Bellevue Family Practice, 2206 Longo Suite 201 - Bellevue
- Complete Children's Health, 8201 Northwoods Drive - Lincoln
- Meridian Clinical Research, 3319 North, 107th Street - Omaha
California
- Prairie Fields Family Medicine, 350 W. 23rd Street, Suite A - Fremont
- Madera Family Medical Group, 1111 W. Fourth Street - Madera
Florida
- Dayton Clinical Research, 1100 Salem Ave - Dayton
- Altamonte Pediatric Associates, 101 N. Country Club Rd. #113 - Lake Mary
Alabama
- Birmingham Pediatrics, 806 Saint Vincent's Drive, Suite 615 - Birmingham
Colorado
- Clinical Research Advantage / Colorado Springs Health Partners, 6340 Barnes Road - Colorado Springs
Georgia
- Pediatrics and Adolescent Medicine, 2155 Post Oak Tritt Road, Suite 100 - Marietta
Iowa
- Clinical Research Advantage / Ridge Family Physicians, 201 Ridge Street, Suite 201 - Council Bluffs
Maryland
- Columbia Medical Practice, 5450 Knoll North Drive, Suite 215 - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01424644
The ClinicalTrials.gov registry entry for NCT01424644 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 541-participant average among 4 other Meningococcal Meningitis trials with a reported enrollment target (48% higher). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningococcal Meningitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine is the first listed.
NCT01424644 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Nebraska, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01424644 about?
NCT01424644 is a clinical study titled "A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents". The main objective is to determine whether immune responses to Tdap (GlaxoSmithKline, Boostrix®) and HPV vaccine (Merck \& Co., Inc., Gardasil®) when administered concomitantly with MenACWY are comparable to responses elicited by these vaccines when given alone.
What is the current status of trial NCT01424644?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 801 participants. The study started on 2011-09. Estimated completion is 2012-12.
What conditions does trial NCT01424644 study?
This clinical trial studies the following conditions: Meningococcal Meningitis.
What interventions are being tested in trial NCT01424644?
The interventions under investigation include: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine (BIOLOGICAL), MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01424644?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01424644 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningococcal Meningitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
COMPLETED · Phase 1
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.